Shilpa Medicare gets compliance letter from USFDA for 2 units

Drug maker Shilpa Medicare Ltd on Thursday said it has received compliance letter from USFDA for its two API manufacturing sites located at Karnataka. “The company has received compliance letter from USFDA for both API manufacturing sites located at Raichur, Karnataka, India (Unit-1: Deosugur Industrial Area, Deosugur, Raichur, Karnataka, India and Unit-2: Raichur Industrial Growth Centre, Chicksugur, Raichur, Karnataka, India),” Shilpa Medicare Ltd said in a filing to the Bombay Stock Exchange on February 11, 2016. Meanwhile, shares of the company were trading at Rs 423.35 apiece, up 1.58 per cent, from previous close on BSE at 11:54 hours.